Drug therapy of severe hypercholesterolemia.
Lowering of plasma cholesterol and particularly of LDL cholesterol has been shown to be an effective way of primary and secondary prophylaxis of coronary heart disease. A broad range of drugs is available (bile acid binding resins, HMG CoA reductase inhibitors, fibrates, nicotinic acid, probucol, beta-sitosterol) for therapy. The choice of the drug is based on the efficacy, possible side effects and proven effects on coronary heart disease.
Weizel
A
A
Med. Klinik des Heinrich Lanz Krankenhauses, Feldbergstr. 68-70, Mannheim D-68163, Germany.
Richter
W O
WO
D000328:Adult; D000837:Anion Exchange Resins / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000627:therapeutic use; D002411:Cation Exchange Resins / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006913:Hydroxysteroid Dehydrogenases; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008562:Membrane Glycoproteins; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
D000837:Anion Exchange Resins; D000924:Anticholesteremic Agents; D002352:Carrier Proteins; D002411:Cation Exchange Resins; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006913:Hydroxysteroid Dehydrogenases; D000960:Hypolipidemic Agents; D008562:Membrane Glycoproteins; C037643:bile acid binding proteins; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)